Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

Verified by: AstraZeneca, October 2009
First Received: June 30, 2009 | Last Updated: October 23, 2009 | Phase: N/A | Start Date: July 2009
Overall Status: Completed | Estimated Enrollment: 3000
  • …
  • Tell a FriendPrint

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group...

Brief Summary

Official Title: “Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients”

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.

  • Study Type: Observational
  • Study Design: Observational Model: Cohort, Time Perspective: Retrospective

Arms, Groups and Cohorts in this Clinical Trial

  • : 3000 patients
    • Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Outcome Measures for this Clinical Trial

Primary Measures

  • Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment)
    • Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation.
      Safety Issue?: No

Secondary Measures

  • Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment)
    • Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation.
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
  • Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
  • Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: AstraZeneca Industry

Overall Clinical Trial Officials and Contacts

Hyunah Caroline Choi Study Director AstraZeneca Korea  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00931320

Study ID Number: NIS-CKR-DUM-2009/3

ClinicalTrials.gov Identifier: NCT00931320

Health Authority: Korea: Food and Drug Administration

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00931320